Key result
The combination of 1.2 mg/kg rocuronium and 10 mg/kg sugammadex was effectively and safely used to induce and antagonize neuromuscular block for 8 ECT sessions in a patient with Brugada syndrome.
Why the study?
Is the combination of rocuronium and sugammadex safe and effective for neuromuscular blockade during electroconvulsive therapy in a patient with Brugada syndrome?
Case Report (n=1)
Is the combination of rocuronium and sugammadex safe and effective for neuromuscular blockade during electroconvulsive therapy in a patient with Brugada syndrome?
Rocuronium and sugammadex can be safely used for neuromuscular blockade during ECT in patients with Brugada syndrome, avoiding vagotonic agents like suxamethonium and neostigmine.
Hypothesis-generating for rocuronium-sugammadex in ECT for Brugada syndrome; does not yet support practice change.
We report the successful anesthetic management of a patient with Brugada syndrome who underwent electroconvulsive therapy to treat bipolar disorder. Suxamethonium and neostigmine were contraindicated to avoid the vagotonic effects that can precipitate ventricular fibrillation during anesthesia in patients with Brugada syndrome. The combination of 1.2 mg/kg rocuronium and 10 mg/kg sugammadex was effectively and safely used to induce and antagonize neuromuscular block for 8 consecutive electroconvulsive therapy sessions in this patient.
No takes yet. Share an insight, caveat, or question.
Konishi et al. (2012) conducted a case report in Brugada syndrome and bipolar disorder (n=1). Rocuronium and Sugammadex was evaluated on Successful anesthetic management (induction and antagonism of neuromuscular block). The combination of 1.2 mg/kg rocuronium and 10 mg/kg sugammadex was effectively and safely used to induce and antagonize neuromuscular block for 8 ECT sessions in a patient with Brugada syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: